THE Australian Medical
Association and the Royal
Australian and NZ College of
Ophthalmologists says they strongly
disagree with this month’s
rescheduling of chloramphenical
eye drops from prescription-only to
S3, with RANZCO President Dr
Richard Stawell saying the
medicine should be reserved for
bacterial eye infections.
“Pharmacists have not been
trained to be competent in
diagnosing eye disease and do not
have the appropriate equipment to
properly examine an eye,” he said.
“It is very important that it is not
used indiscriminately,” Stawell added.The above article was sent to subscribers in Pharmacy Daily's issue from 07 May 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 May 10
STRONG growth in Australia has helped MedAdvisor Solutions achieve robust results for FY24, with a revenue increase of 24.6% on the previous corresponding period to $122.1 million.
WESFARMERS has today reported strong growth in revenue across its Health division and its Australian Pharmaceutical Industries (API) subsidiary, despite a significant reduction in COVID-19 anti-viral product sales.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.